Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16444882 | 1.00 | GAA (0.53) | GAAOPRM1OPRD1OPRK1GRIN2D | |
| SCHEMBL16454918 | 0.88 | GAA (0.54) | GAAOPRM1OPRD1OPRK1GRIN2D | |
| SCHEMBL16445412 | 0.88 | GAA (0.67) | GAAOPRM1OPRD1OPRK1LMNA | |
| SCHEMBL20820915 | 0.85 | GAA (0.37) | GAAOPRM1OPRD1OPRK1GRIN2D | |
| SCHEMBL16451334 | 0.84 | GAA (0.56) | GAAOPRM1OPRD1OPRK1GRIN2D | |
| SCHEMBL16451316 | 0.84 | GAA (0.56) | GAAOPRM1OPRD1OPRK1GRIN2D | |
| SCHEMBL21600566 | 0.83 | GAA (0.73) | GAAOPRM1OPRD1OPRK1GRIN2D | |
| SCHEMBL22865971 | 0.83 | GAA (0.73) | GAAOPRM1OPRD1OPRK1GRIN2D | |
| SCHEMBL21600228 | 0.83 | GAA (0.73) | GAAOPRM1OPRD1OPRK1GRIN2D | |
| SCHEMBL16445988 | 0.83 | GAA (0.73) | GAAOPRM1OPRD1OPRK1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158017-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-25 | — | — | US | disclosed |
| US-11534436-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-12-27 | — | — | US | disclosed |
| US-20210000818-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-01-07 | — | — | US | disclosed |
| US-10736890-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-08-11 | — | — | US | disclosed |
| US-20190167666-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-06-06 | — | — | US | disclosed |
| US-10287250-B2 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-05-14 | — | — | US | disclosed |
| US-20180016237-A1 | Morphan And Morphinan Analogues, And Methods Of Use | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-01-18 | — | — | US | disclosed |
| US-9682936-B2 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-20 | — | — | US | disclosed |
| US-9656961-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167666-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | GAA 1347/4885OPRM1 1/4885OPRD1 4/4885 |
| US-20210000818-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | GAA 1347/4885OPRM1 1/4885OPRD1 4/4885 |
| US-10287250-B2 | Morphan and morphinan analogues, and methods of use | MTPN, UTRN, FSCN1 | GAA 374/4885OPRM1 159/4885OPRD1 642/4885 |
| US-20180016237-A1 | Morphan And Morphinan Analogues, And Methods Of Use | MTPN, UTRN, FSCN1 | GAA 398/4885OPRM1 159/4885OPRD1 666/4885 |
| US-20230158017-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | GAA 1347/4885OPRM1 1/4885OPRD1 4/4885 |
| US-11534436-B2 | Methods for treating depressive symptoms | OPRM1, OPRL1, OPRK1 | GAA 1347/4885OPRM1 1/4885OPRD1 4/4885 |
| US-10736890-B2 | Methods for treating depressive symptoms | OPRM1, OPRL1, OPRK1 | GAA 1347/4885OPRM1 1/4885OPRD1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.